GSK (GSK) vs Pfizer (PFE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
GSK (GSK) has outperformed Pfizer (PFE) over the past year, gaining 8.1% versus a gain of 6.6%. Over five years, GSK leads with a +20.5% price change compared with -32.5% for PFE. Pfizer is the larger company by market cap ($158.39 billion vs $93.10 billion), about 1.7 times the size.
On valuation, GSK trades at a lower forward P/E (9.4x vs 9.6x for Pfizer). Pfizer offers the higher dividend yield (6.19% vs 1.46%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GSK | PFE |
|---|---|---|
| Share price | $46.47 | $27.79 |
| Market cap | $93.10B | $158.39B |
| 1-day change | -1.17% | -0.75% |
| YTD return | -4.12% | +12.45% |
| 1-year return | +8.09% | +6.59% |
| 5-year return | +20.53% | -32.51% |
| P/E ratio (TTM) | 14.66 | 36.56 |
| Forward P/E | 9.40 | 9.59 |
| EPS (TTM) | $3.17 | $0.76 |
| Dividend yield | 1.46% | 6.19% |
| Annual dividend | $0.68 | $1.72 |
| Revenue (latest FY) | — | $62.58B |
| Revenue growth (YoY) | — | -1.65% |
| Net income (latest FY) | — | $7.77B |
| Gross margin | — | 74.33% |
| Net margin | — | 12.42% |
| 52-week high | $61.70 | $29.21 |
| 52-week low | $42.85 | $23.62 |
| Distance from 52-week high | -24.68% | -4.86% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +27.67% | +4.03% |
| Average volume | 3.77M | 35.94M |
| Shares outstanding | 2.00B | 5.70B |
| Employees | 66,841 | 75,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Pfizer trades at a higher earnings multiple (36.6x vs 14.7x trailing P/E).
- Pfizer offers a meaningfully higher dividend yield (6.19% vs 1.46%).
About GSK
GSK stock →GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 66,841 employees
About Pfizer
PFE stock →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 75,000 employees
GSK vs PFE FAQ
Which is bigger, GSK or Pfizer?
Pfizer (PFE) is larger, with a market capitalization of $158.39B compared with $93.10B for GSK (GSK).
Which stock has performed better over the past year, GSK or PFE?
GSK returned +8.09% over the past 12 months, compared with +6.59% for PFE (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GSK or PFE?
GSK has the lower trailing P/E at 14.7, versus 36.6 for PFE. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, GSK or Pfizer?
Pfizer has the higher yield at 6.19%, compared with 1.46% for GSK.
Are GSK and Pfizer in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.